Clinical Trial Update: Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection [Phase 2]

View source ↗

Summary

Phase 2 trial of VE303 for prevention of recurrent Clostridioides difficile infection has completed; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection
• Clostridium Difficile Infection

Drugs mentioned

• VE303

Snippet

Sponsor: Vedanta Biosciences, Inc. | Conditions: Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection | Phase 2 | Status: COMPLETED | Results posted: 2023-07-03